- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01274351
Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
A Phase II Multi-center, Open-label, Non-randomized Study of Nilotinib as First Line Treatment in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)
Study Overview
Detailed Description
This was a multicenter, open-label, single-arm, phase 2 study of nilotinib as a frontline treatment for patients with Ph+ CMLCP. All patients received oral nilotinib 300 mg twice daily for a planned treatment duration of 24 months or until early discontinuation.
The primary efficacy end point was the cumulative rate of Major Molecular Response (MMR) in all participants by 12 months. Secondary efficacy end points included the rate of Complete Cytogenic Response (CCyR) at 6 and 12 months; cumulative rates of MMR up to 24 months; time to and durability of MMR; and cumulative rate of Complete Haematologic Response (CHR) by 12 months.
Patient evaluations, including hematologic assessments, were conducted every 15 days during the first 3 months, monthly until month 12, and then every 3 months until the end of the study (24 months). All efficacy analyses were performed in the intent-to treat population.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Adana, Turkey, 01330
- Novartis Investigative Site
-
Ankara, Turkey, 06100
- Novartis Investigative Site
-
Bursa, Turkey, 16059
- Novartis Investigative Site
-
Diyarbakir, Turkey, 21000
- Novartis Investigative Site
-
Gaziantep, Turkey, 27310
- Novartis Investigative Site
-
Istanbul, Turkey, 34093
- Novartis Investigative Site
-
Izmir, Turkey, 35040
- Novartis Investigative Site
-
Izmir, Turkey, 35340
- Novartis Investigative Site
-
Okmeydani, Turkey, 34370
- Novartis Investigative Site
-
Talas / Kayseri, Turkey, 38039
- Novartis Investigative Site
-
Trabzon, Turkey, 61080
- Novartis Investigative Site
-
-
Meselik
-
Eskisehir, Meselik, Turkey, 26480
- Novartis Investigative Site
-
-
TUR
-
Istanbul, TUR, Turkey, 34098
- Novartis Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- First cytogenetic diagnosis of CML-CP with cytogenetic confirmation of Philadelphia chromosome of (9;22) translocations within 6 months. Standard conventional cytogenetic analysis must be performed.
- Previously untreated for CML, except for hydroxyurea and/or anagrelide (except imatinib treatment for max. 31 days long)
- Adequate end organ function with following laboratory criteria: total bilirubin < 1.5 x upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x upper limit of normal (ULN); creatinine < 1.5 x upper limit of normal (ULN); serum amylase and lipase ≤ 1.5 x upper limit of normal (ULN); alkaline phosphatase ≤ 2.5 x upper limit of normal (ULN) unless considered tumor related
- Serum potassium, magnesium, and phosphorus levels are equal or above the lower limit of normal prior to the first dose of study medication
Exclusion Criteria:
- Treatment with tyrosine kinase inhibitor(s) prior to study (in emergent cases where the patient requires disease management while awaiting study start, commercial supplies of imatinib at any dose may be prescribed to the patient but for no longer than 31 days in duration)
- Known cytopathologically confirmed Central Nervous System CNS infiltration
- Impaired cardiac function
- Severe or uncontrolled medical conditions (i.e. uncontrolled diabetes, active or uncontrolled infection)
- Acute or chronic liver, pancreatic or severe renal disease considered unrelated to disease
- Patients with another primary malignancy except if the other primary malignancy is neither currently clinically significant or requiring active intervention
- History of significant congenital or acquired bleeding disorder unrelated to cancer
- Previous radiotherapy to ≥25% of the bone marrow
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study drug (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection, or gastric bypass surgery)
- Use of therapeutic coumarin derivatives (i.e. warfarin, acenocoumarol, phenprocoumon)
- Patients actively receiving therapy with strong Cytochrome P450 3A4 isoenzyme (CYP3A4) inhibitors (e.g, erythromycin, ketoconazole, itraconazole, voriconazole, clarithromycin, telithromycin, ritonavir, mibefradil)
- Patients actively receiving therapy with medications that have the potential to prolong the QT interval and the treatment cannot be either discontinued or switched to a different medication prior to starting study drug
Other protocol-defined inclusion/exclusion criteria may apply
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Nilotinib
administered orally at a dose of 300 mg twice daily for 24 months
|
administered orally at a dose of 300 mg twice daily for 24 months
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Achieved Major Molecular Response (MMR) During the First 12 Months
Time Frame: 12 months
|
Major Molecular Response (MMR) was defined as BCR-ABL1^IS ≤0.1%, on the International Scale [BCR-ABL1IS]) by 12 months.
BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene.
BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL.
Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants Who Achieved Major Molecular Response (MMR) up to 24 Months
Time Frame: 3, 6, 9, 15, 18, 21 and 24 months
|
Major Molecular Response (MMR) was defined as BCR-ABL1^IS ≤0.1%, on the International Scale [BCR-ABL1IS]) by 12 months.
BCR is the Breakpoint Cluster Region gene / BCR gene product and ABL is the Abelson proto-oncogene.
BCR-ABL is the Fusion gene from BCR and ABL/Protein product from BCR-ABL.
Participants who withdrew prematurely or those who failed to provide data for the study for other reasons were designated as premature withdrawal or inevaluable, respectively, and were included in the ITT analysis as non-responders.
|
3, 6, 9, 15, 18, 21 and 24 months
|
Percentage of Participants With Complete Cytogenetic Response (CCyR) at Month 6 and 12
Time Frame: Month 6 and 12
|
CCyR rate is identified as the rate of patients who had 0% of Ph+ metaphase.
|
Month 6 and 12
|
Percentage of Participants With Complete Hematologic Response (CHR) at Month 3, 6, 9, 12, 18 and 24
Time Frame: Month 3, 6, 9, 12, 18 and 24
|
A confirmed complete hematological response (CHR) is defined when all of the following criteria are achieved: WBC <10 x 109/L, thrombocyte <450 x 109/L, myelocyte + metamyelocyte <%5 in blood, no sign of blast and promyelocyte in blood, basophil <%5, and no sign of extramedullary involvement.
|
Month 3, 6, 9, 12, 18 and 24
|
Time to Major Molecular Response (MMR)
Time Frame: 24 months
|
Time to MMR is defined as the time period from the date of first dose intake until the first documented MMR.
|
24 months
|
Duration of Major Molecular Response (MMR)
Time Frame: 24 months
|
MMR duration is defined as the time from the date of first documented MMR to the first time of the lost MMR, progression or death.
|
24 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akin G, Dag IM, Ilhan O. Frontline nilotinib treatment in Turkish patients with Philadelphia chromosome-positive chronic Myeloid Leukemia in chronic phase: updated results with 2 years of follow-up. Hematology. 2018 Dec;23(10):771-777. doi: 10.1080/10245332.2018.1498167. Epub 2018 Jul 11.
- Saydam G, Haznedaroglu IC, Kaynar L, Yavuz AS, Ali R, Guvenc B, Akay OM, Baslar Z, Ozbek U, Sonmez M, Aydin D, Pehlivan M, Undar B, Dagdas S, Ayyildiz O, Akkaynak DZ, Akin G, Ilhan O. Outcomes with frontline nilotinib treatment in Turkish patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Hematology. 2018 Feb 27:1-7. doi: 10.1080/10245332.2018.1444919. Online ahead of print.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CAMN107ETR02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Myelogenous Leukemia
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)CompletedChildhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
National Cancer Institute (NCI)TerminatedAccelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
National Cancer Institute (NCI)CompletedChronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 PositiveUnited States
-
M.D. Anderson Cancer CenterNovartisCompletedLeukemia, Myelogenous, ChronicUnited States
-
The University of Hong KongUnknownCessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous LeukaemiaLeukemia, Myelogenous, Chronic PhaseHong Kong
-
National Cancer Institute (NCI)CompletedAccelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous LeukemiaUnited States
-
Assiut UniversityUnknownChronic Phase Chronic Myelogenous Leukemia
Clinical Trials on Nilotinib
-
Niguarda HospitalCompletedLeukemia, Myeloid, Chronic-PhaseItaly
-
Novartis PharmaceuticalsTerminatedPulmonary Arterial HypertensionSwitzerland, United States, Germany, Singapore, Korea, Republic of, Canada
-
Georgetown UniversityUnknownParkinson Disease | Parkinsons Disease With DementiaUnited States
-
XSpray MicroparticlesCompleted
-
Shenzhen Second People's HospitalDongguan People's Hospital; Zhongshan People's Hospital, Guangdong, China; The... and other collaboratorsRecruitingChronic Myeloid Leukemia, Chronic Phase | NilotinibChina
-
Andrew J. Wagner, MD, PhDMassachusetts General Hospital; Novartis; Brigham and Women's HospitalActive, not recruitingTenosynovial Giant Cell Tumor | Pigmented Villonodular Synovitis | Diffuse-type Giant Cell TumorUnited States
-
Novartis PharmaceuticalsNo longer availableHypereosinophilic Syndrome (HES)
-
KeifeRx, LLCWorldwide Clinical Trials; Life Molecular Imaging GmbH; Sun Pharmaceuticals Industries...Not yet recruiting
-
Novartis PharmaceuticalsNo longer availableAcute Lymphoblastic Leukemia (ALL)
-
Novartis PharmaceuticalsCompleted